Al-Qassabi and colleagues recently published a study in Movement Disorders that examined whether 3-mm skin punch biopsies could be used to detect synuclein pathology in patients with REM sleep behavior disorder (RBD).
CND Life Sciences continues to increase awareness and adoption of the skin-based Syn-One Test™ for Parkinson’s disease, dementia with Lewy bodies, and other synucleinopathies, now with the new “Power of Proof” campaign, which will appear across several top neurology journals and websites.
At the 2021 American Academy of Neurology meeting last month, Dr Alexandru Barboi and colleagues presented their observations on the use of the Syn-One Test™ in the evaluation of patients with autonomic symptoms.
A team of skilled laboratory professionals are the engine that keeps CND Life Sciences running every day. From the moment a Syn-One Test™ sample arrives, it must be handled and processed according to strict specifications.
In the next installment of our Patient Matters video series, Daryn Kagan talks with Alvin, a patient who was living with unexplained fatigue in his legs.
In a new effort to increase awareness and adoption of the skin-based Syn-One Test™ for Parkinson’s disease, dementia with Lewy bodies, and other synucleinopathies, CND has launched a targeted print and digital campaign across several top neurology journals and websites.
A core value of CND Life Sciences is putting patients first. We understand that there’s a patient behind every Syn-One Test™ we perform. That’s why we’re launching the Patient Matters video series—hosted by former CNN anchor Daryn Kagan—to bring those patients’ stories to the forefront and demonstrate the importance of the Syn-One Test in helping clinicians make an objective and accurate diagnosis.